Enterprise Value
16.3B
Cash
1.047B
Avg Qtr Burn
N/A
Short % of Float
3.96%
Insider Ownership
0.87%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOXZOGO (vosoritide) Details Achondroplasia, Genetic Short Stature Conditions | Approved Quarterly sales | |
Approved Quarterly sales | ||
VOXZOGO (vosoritide) Details Achondroplasia, Genetic Short Stature Conditions | Approved Quarterly sales | |
VOXZOGO Details Hypochondroplasia | Phase 2 Initiation |